The vertebrate cornea is an avascular tissue and does not contain elastic fibers. We tested the capacity of corneal epithelial cells and stromal keratocytes to synthesize tropoelastin. Explant cultures and cell cultures were obtained from these two cell types in standard culture conditions. Their elastin-synthetic activity was compared to skin explant cultures and to dermal fibroblast cell cultures. Both corneal cell types synthesized tropoelastin as shown by the incorporation of a radioactive precursor followed by immunoprecipitation of tropoelastin. When serial cultures of keratocytes were tested, tropoelastin biosynthesis strongly increased after the 3rd passage and was at the 9th passage more than the double of that of the first passage. When cocultures were studied with or without cell contact, epithelial cells partially inhibited tropoelastin biosynthesis by keratocytes. This inhibition was somewhat stronger (–36%, p < 0.005) with cell-to-cell contact than keeping separate epithelial cells and keratocytes bathing in the same medium (–18%, p < 0.005). When human skin fibroblasts were substituted for keratocytes with cell-to-cell contact, their tropoelastin biosynthesis was also inhibited by corneal epithelial cells (–42%, p < 0.005), to the same extent as for keratocytes. In Transwell culture, this inhibition was again somewhat lower (–36%, p < 0.005). Some diffusible factor produced by epithelial cells is apparently involved. The epithelial inhibition of tropoelastin biosynthesis by stromal keratocytes might represent one of the mechanisms keeping corneal stroma exempt of elastin fibers.

Keywords:
Elastin, Tropoelastin, Cornea, Keratocytes, Epithelial cells, Dermal fibroblast
1.
Alexander RA, Garner A: Elastic and precursor fibers in the normal eye. Exp Eye Res 1983;36:305–315.
2.
Daga Gordini D, Castellani I, Volpin D, Bressan GM: Ultrastructural immunolocalisation of tropoelastin in the chick eye. Cell Tissue Res 1990;260:137–146.
3.
Dubord PJ, Rodrigues MM, Krachmer JH: Corneal elastosis in lattice corneal dystrophy: A clinicopathologic report. Ophthalmology 1981;88:1239–1243.
4.
Pe’er J, Fine BS, Dixon A, Rothberg DS: Corneal elastosis within lattice dystrophy lesions. Br J Ophthalmol 1988;72:183–188.
5.
Kampik A, Sani JN, Green WR: Ocular ochronosis: Clinicopathological, histochemical and ultrastructural studies. Arch Ophthalmol 1980;98:1441–1447.
6.
Colombatti A, Poletti A, Bressan GM, Carbone A, Volpin D: Widespread codistribution of glycoprotein gp 115 and elastin in chick eye and other tissues. Coll Relat Res 1987;7:259–275.
7.
Hirano K, Kobayashi M, Kobayashi K, Hoshino T, Awaya S: Age-related changes of microfibrils in the cornea and trabecular meshwork of the human eye. Jpn J Ophthalmol 1991;35:166–174.
8.
Gregory C, Sephel BS, Davidson JM: Elastin production in human skin fibroblast cultures and its decline with age. J Invest Dermatol 1986;86:279–285.
9.
Tajima S, Wachi H, Uemura Y, Okamoto K: Modulation by elastin peptide VGVAPG of cell proliferation and elastin expression in human skin fibroblasts. Arch Dermatol Res 1997;289:489–492.
10.
Mecham RP, Lange G, Madaras J, Statcher B: Elastin synthesis by ligamentum nuchae fibroblasts: Effect of culture conditions and extracellular matrix on elastin production. J Cell Biol 1981;90:332–338.
11.
Rosenbloom J, Abrams WR, Mecham RP: Extracellular matrix: The elastic fiber. FASEB J 1993;7:1208–1218.
12.
Davidson JM: Regulation of elastin gene expression; in Robert L, Hornebeck W (eds): Elastin and Elastases. Boca Raton, CRC Press, 1989, vol I, pp 83–90.
13.
Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg G, Welgus H: Human 92- and 72-kD type IV collagenases are elastases. J Biol Chem 1991;266:7870–7875.
14.
Hayflick L, Moorhead PS: The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585–621.
15.
Hinek A, Rabinovitch M: 67 kDa elastin binding protein is a protective ‘companion’ of extracellular insoluble elastin and intracellular tropoelastin. J Cell Biol 1994;126:563–574.
16.
Boyer B, Kern P, Fourtanier A, Labat-Robert J: Age-dependent variations of the biosynthesis of fibronectin and fibrous collagens in mouse skin. Exp Gerontol 1991;26:375–383.
17.
Labat-Robert J, Kern P, Robert L: Biomarker of connective tissue aging: Biosynthesis of fibronectin, collagen type III and elastase. Ann NY Acad Sci 1992;673:16–22.
18.
Labat-Robert J, Fourtanier A, Boyer-Lafargue B, Robert L: Age dependent increase of elastase type protease activity in mouse skin: Effect of UV irradiation. J Photochem Photobiol B 2000;57:113–118.
19.
Isnard N, Legeais JM, Renard G, Robert L: Effect of hyaluronan on MMP expression and activation. Cell Biol Int 2001;25:735–739.
20.
Reim M, Luthe P: Compartmentation of redox metabolites in the anterior eye segment? Albrecht Von Graefes Arch Klin Exp Ophthalmol 1977;204:135–140.
21.
Mecham RP, Lange G, Madaras J, Starcher B: Elastin synthesis by ligamentum nuchae fibroblasts: Effects of culture conditions on extracellular matrix on elastin production. J Cell Biol 1981;90:332–338.
22.
Davidson JM, LuValle PA, Zoia O, Quaglino D, Giro MG: Ascorbate differentially regulates elastin and collagen biosynthesis in vascular smooth muscle cells and skin fibroblasts by pretranslational mechanisms. J Biol Chem 1997;272:345–352.
© 2004 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.